Our identification of a role for MAD2L2/REV3L in fork protection and fork restart in absence of DNA lesions, such as upon nucleotide reduction, suggests a wider potential for MAD2L2/REV3L inhibition, or for exploiting MAD2L2/REV3L expression status, in cancer treatment, that would be worth to explore. Here, REV3L is linked to cancer.